景業智能(688290.SH):已完成四足和人形形態的機器人研發立項
格隆匯12月30日丨景業智能(688290.SH)在互動平台表示,①2024年下半年以來,公司各業務板塊的下游訂單逐步恢復企穩,目前在手訂單充足。展望2025年,公司緊扣發展戰略,秉持“核+軍+民”梯隊式發展,不斷優化業務佈局,確保訂單順利交付。②在核軍機器人產品方面,公司已完成四足和人形形態的機器人研發立項,並制定了相應的研發計劃。未來,公司將立足於現有賽道的技術積累優勢,繼續發力,專注於拓展特種領域機器人市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.